Summit Therapeutics (SMMT) Misses Q2 EPS by 3c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.12), GBP0.03 worse than the analyst estimate of (GBP0.09).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
- Google opens pre-orders for AI-powered Googlebook laptops
- Increasing unusual call option volume: EH WU CRDU DC CYPH BWXT DBC BMEA BURL
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
